RT Journal Article SR Electronic T1 Consensus-based care recommendations for adults with myotonic dystrophy type 2 JF Neurology: Clinical Practice FD Lippincott Williams & Wilkins SP 343 OP 353 DO 10.1212/CPJ.0000000000000645 VO 9 IS 4 A1 Schoser, Benedikt A1 Montagnese, Federica A1 Bassez, Guillaume A1 Fossati, Barbara A1 Gamez, Josep A1 Heatwole, Chad A1 Hilbert, James A1 Kornblum, Cornelia A1 Kostera-Pruszczyk, Anne A1 Krahe, Ralf A1 Lusakowska, Anna A1 Meola, Giovanni A1 Moxley, Richard A1 Thornton, Charles A1 Udd, Bjarne A1 Formaker, Paul A1 , YR 2019 UL http://cp.neurology.org/content/9/4/343.abstract AB Purpose of review Myotonic dystrophy type 2 (DM2) is a rare, progressive multisystem disease particularly affecting the skeletal muscle. A causal therapy is not yet available; however, prompt, appropriate symptomatic treatments are essential to limit disease-related complications. Evidence-based guidelines to assist medical practitioners in the care of DM2 patients do not exist.Recent findings The Myotonic Dystrophy Foundation (MDF) previously worked with an international group of 66 clinicians to develop consensus-based care recommendations for myotonic dystrophy type 1. Following a similar approach, the MDF recruited 15 international clinicians with long-standing experience in the care of DM2 patients to develop consensus-based care recommendations. The single text procedure was adopted. This process generated a 4-page Quick Reference Guide and a comprehensive 55-page document that provides care recommendations for DM2 patients.Summary The resulting recommendations will help standardize and improve care for DM2 patients and facilitate appropriate management in centers without neuromuscular specialists.